Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Fuji Biomedix Develops Kit to Diagnose Malignancy of Colon Cancer
February 20, 2006
- Aiming at \10 Bil. Sales with Seibule: Sanwa Kagaku
February 20, 2006
- ＜OPINION＞ Romancing the Right Remuneration
February 20, 2006
- R&D NEWS IN BRIEF
February 20, 2006
- Dr M. Angell's Book Publication Seminar
February 20, 2006
- Univ. Hospitals Should Improve Infrastructure for TR: Prof. Fukushima
February 20, 2006
- APDD to Promote Clinical Trials
February 20, 2006
- ＜Symposium＞ "Tamiflu Should Not Be Used": Medwatcher Japan
February 20, 2006
- REGULATORY NEWS IN BRIEF
February 20, 2006
- Chuikyo's Reform to Take Place in March 2007
February 20, 2006
- Bill Payers, Care Providers Clash on Mandatory Receipts
February 20, 2006
- Chugai to Start Big Leap Forward in 2006
February 20, 2006
- Bills for Healthcare Reform Approved by Cabinet
February 20, 2006
- Eisai Acquires Exclusive Rights to Prialt in Europe
February 20, 2006
- FTC to Investigate Ethical Drug Business Practices
February 20, 2006
- Early Discovery, Family Understanding Important to Treat OCD: GSK Seminar
February 20, 2006
- BUSINESS NEWS IN BRIEF
February 20, 2006
- JASDI Forum on Drug Information Needed by Patients
February 20, 2006
- 188th PMAT Seminar
February 20, 2006
- MEDICAL DEVICE NEWS IN BRIEF
February 20, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…